Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01499628
Other study ID # RUBG1008
Secondary ID Fight for Sight
Status Completed
Phase N/A
First received
Last updated
Start date April 27, 2011
Est. completion date December 31, 2015

Study information

Verified date December 2023
Source Moorfields Eye Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in the UK, Europe and N America. Low vision patients with AMD have great difficulty reading, which leads to a loss of independence and reduced quality of life. Magnifiers alone do not compensate for loss of central vision in AMD. It has been proposed that special low vision training can improve reading ability in patients with AMD. Training programmes are widely available in the US and Scandinavia, but not in the UK, partly because there is a lack of evidence from Randomised Control Trials (RCT) showing that they are effective. The investigators are conducting a clinical trial comparing the conventional hospital-based low vision service to enhanced rehabilitation programmes that include Eccentric Viewing training. Eccentric viewing training involves teaching patients who have lost their central vision to use a new area of retina for visual tasks. Patients are either taught to improve the use of the part of the retina they naturally start using after their central vision is lost, their so-called preferred retinal locus (PRL), or, alternatively, they are taught to use a different retinal area that is thought to be better suited for everyday visual tasks, the so-called trained retinal locus (TRL). The investigators plan to compare the two types of eccentric viewing training to conventional hospital-based low vision care.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 31, 2015
Est. primary completion date November 26, 2015
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Diagnosis of age-related macular degeneration - Visual acuity 6/12 to 3/60 inclusive in the better eye - Dense central scotoma confirmed by microperimetry Exclusion Criteria: - Patients who are not fluent in English or are cognitively impaired - Patients with serious hearing impairment - Patients who are hospital inpatients, who are living in nursing homes or are otherwise non-independent - Ocular co-morbidity (other than mild cataract) in the better eye - Recent low vision assessment or eccentric viewing training

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Supervised Reading
Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
EVT at the PRL
Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
EVT at the TRL
Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.

Locations

Country Name City State
United Kingdom Moorfields Eye Hospital London

Sponsors (2)

Lead Sponsor Collaborator
Moorfields Eye Hospital NHS Foundation Trust British Eye Research Foundation, operating as Fight for Sight

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Score on the Massof Activity Inventory - 6 month follow up Change from Baseline in Massof Activity Inventory at 6 month follow up
Secondary Reading Speed (ReST) - Final Assessment Change from Baseline in Reading Speed (ReST) at Final Assessment
Secondary Quality of Life (MacDQoL) - Final Assessment Change from Baseline in Quality of Life (MacDQoL) at Final Assessment
Secondary Quality of Life (MacDQoL) - 6 month follow up Change from Baseline in Quality of Life (MacDQoL) at 6 month follow up
Secondary Quality of Life (MacDQoL) - 12 month follow up Change from Baseline in Quality of Life (MacDQol) at 12 month follow up
Secondary Self-reported health status (EQ-5D) - Final Assessment Change from Baseline in EQ-5D score at Final Assessment
Secondary Self-reported health status (EQ-5D) - 6 month follow up Change from Baseline in EQ-5D score at 6 month follow up
Secondary Self-reported health status (EQ-5D) - 12 month follow up Change from Baseline in EQ-5D score at 12 month follow up
Secondary Time Trade Off (TTO) - 6 month follow up Change from Baseline in Time Trade Off (TTO) score at 6 month follow up
Secondary WHO (Five) Well-Being Index (WBI-5) - Final Assessment Change from Baseline in WBI-5 score at Final Assessment
Secondary WHO (Five) Well-Being Index (WBI-5) - 6 month follow up Change from Baseline in WBI-5 score at 6 month follow up
Secondary WHO (Five) Well-Being Index (WBI-5) - 12 month follow up Change from Baseline in WBI-5 score at 12 month follow up
Secondary Interpersonal Support Evaluation List (ISEL) - Final Assessment Change from Baseline in Interpersonal Support Evaluation List (ISEL) at Final Assessment
Secondary Interpersonal Support Evaluation List (ISEL) - 6 month follow up Change from Baseline in Interpersonal Support Evaluation List (ISEL) at 6 month follow up
Secondary Interpersonal Support Evaluation List (ISEL) - 12 month follow up Change from Baseline in Interpersonal Support Evaluation List (ISEL) at 12 month follow up
Secondary Acceptance and Self Worth Adjustment Scale (AS-WAS) - Final Assessment Change from Baseline in Acceptance and Self Worth Adjustment Scale (AS-WAS) at Final Assessment
Secondary Acceptance and Self Worth Adjustment Scale (AS-WAS) - 6 month follow up Change from Baseline in Acceptance and Self Worth Adjustment Scale (AS-WAS) at 6 month follow up
Secondary Acceptance and Self Worth Adjustment Scale (AS-WAS) - 12 month follow up Change from Baseline in Acceptance and Self Worth Adjustment Scale (AS-WAS) at 12 month follow up
Secondary Massof Activity Inventory - Final Assessment Change from Baseline in Massof Activity Inventory at Final Assessment
Secondary Massof Activity Inventory - 12 month follow up Change from Baseline in Massof Activity Inventory at 12 month follow up
See also
  Status Clinical Trial Phase
Recruiting NCT04667039 - Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® Phase 3